Difference between revisions of "Bladder cancer - historical"
Jump to navigation
Jump to search
m (Removed redirect to Urothelial carcinoma - historical) Tag: Removed redirect |
m |
||
| Line 13: | Line 13: | ||
=Nonmuscle invasive bladder cancer= | =Nonmuscle invasive bladder cancer= | ||
==Intravesicular Doxorubicin monotherapy {{#subobject:8034b6|Regimen=1}}== | ==Intravesicular Doxorubicin monotherapy {{#subobject:8034b6|Regimen=1}}== | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:49ccdb|Variant=1}}=== | ===Regimen {{#subobject:49ccdb|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 47: | Line 47: | ||
#'''SWOG 8216:''' Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. [https://doi.org/10.1056/NEJM199110243251703 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/1922207/ PubMed] | #'''SWOG 8216:''' Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. [https://doi.org/10.1056/NEJM199110243251703 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/1922207/ PubMed] | ||
==Intravesicular Thiotepa monotherapy {{#subobject:5b9d6c|Regimen=1}}== | ==Intravesicular Thiotepa monotherapy {{#subobject:5b9d6c|Regimen=1}}== | ||
| − | <div class="toccolours" style="background-color:# | + | <div class="toccolours" style="background-color:#ee6b6e"> |
===Regimen {{#subobject:97d2e7|Variant=1}}=== | ===Regimen {{#subobject:97d2e7|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
Revision as of 17:04, 3 November 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main bladder cancer page for current regimens.
2 regimens on this page
2 variants on this page
|
Nonmuscle invasive bladder cancer
Intravesicular Doxorubicin monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Martínez-Piñeiro et al. 1990 | 1980-1988 | Phase 3 (C) | 1. BCG | Inferior RFS |
| 2. Thiotepa | Not reported | |||
| Lamm et al. 1991 (SWOG 8216) | 1983-1985 | Phase 3 (C) | BCG | Seems to have inferior DFS |
Chemotherapy
- Doxorubicin (Adriamycin) 50 mg intravesicularly once on day 1
7-day cycle for 5 cycles, then 30-day cycle for 11 cycles (approximately 1 year)
References
- Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed
- SWOG 8216: Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991 Oct 24;325(17):1205-9. link to original article contains dosing details in manuscript PubMed
Intravesicular Thiotepa monotherapy
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Martínez-Piñeiro et al. 1990 | 1980-1988 | Phase 3 (C) | 1. BCG | Inferior RFS |
| 2. Doxorubicin | Not reported |
Chemotherapy
- Thiotepa (Thioplex) 50 mg intravesicularly x 15 treatments
References
- Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990 Mar;143(3):502-6. link to original article contains partial protocol PubMed